Monthly Archives: June 2021

Global Trac Solutions, Inc. (OTCPink: PSYC), a digital media company focused on the psychedelics sector, published traffic results for its Psychedelic Spotlight news platform.

The company reported record page views of almost 125,000 views for May alone, surpassing the previous record of 105,000 views for April.

Global Trac viewed the data as an indication of the notable growth of interest in psychedelics medicine.

From my perspective, with the psychedelics industry still very much in its infancy, I cant help but to see the advantageous and opportunistic position that, in my opinion, we are creating for PSYC through the success of Psychedelic Spotlight, Global Trac's CEO David Flores said.

Benzingas Take: Benzingas own page views around the keyword psychedelics show a different trend. May was the lowest performing month of the year for the category, which peaked in January 2021.

From a broader perspective, however, the last six months (from December 2020 to May 2021) showed an increase in traffic of almost 300% for the psychedelics category when compared to the six months raging from June 2020 to November 2020.

Photo by Myriam Jessier on Unsplash

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Continue reading here:

Global Trac Solutions Reports Record Pageviews Of Psychedelics Industry Indicate An Expanding Interest In The Sector - Yahoo Finance

In 2014, during my first pregnancy, I felt happy and healthy almost all the time. I rode my bike to work at the Department of Energy & Environment in Washington, D.C., until I was six or seven months pregnant and took kickboxing classes until about four weeks before my daughter was born.

So it was a bit of a shock when my second pregnancy was so different. Around the four-month mark, I developed sciatica, which is intense nerve pain that runs from your pelvis down your leg. By the end of each day, I could barely walk. I had to crawl up the stairs to the bedroom. Because of the pain, I wasnt able to be as active as I wanted. Then other parts of my health started to decline I stopped eating healthy food and doing other things I needed to do to take care of myself physically and mentally.

Courtesy of Subject

I developed whats called antepartum depression, or depression during pregnancy. I had never heard of it, but it's not uncommon about 7% of pregnant women experience it, according to the Mayo Clinic, and many more cases may go unreported. My doctor prescribed an antidepressant, which I know is lifesaving for many people, but for personal reasons I decided not to take it.

I tried to manage my pain with over-the-counter pain relievers, heating pads, warm baths and acupuncture, which did provide some short-term relief. I also tried meditating, but I would just sit there hurting, my mind swirling. In the summer of 2017, I delivered my son, Ramsey. He had a head full of curls and for a couple of weeks, all was well. Then he developed GI issues and we had some other challenges. Plus, going from one kid (my daughter Lola was three) to two doesnt just double the work it quadruples it. I felt so overwhelmed. Other moms I knew seemed like they had it all together. I thought, why am I the only one who's struggling? Id just put on my happy face and pretend like everything was okay. But it wasnt.

By late 2017, I developed severe postpartum depression. It wasnt just profound sadness, it was dread. I had a constant chatter of negative self-talk going on, a voice in my head reminding me what a terrible wife and mother I was. I had a therapist, but the depression made me feel so unmotivated, I'd find any excuse not to go.

That fall, my husband Daniel and I drove down to Alabama with the kids to see his parents for Thanksgiving. A friend of mine suggested that we listen to a podcast that he thought might help me, so we turned it on in the car. The guest on the show was Paul Stamets, a mycologist, or mushroom scientist, who was talking about psilocybin, the psychedelic component of some mushrooms, as a treatment for depression. I've never taken any kind of psychedelic drug, but at that point, I was open to considering just about anything.

Courtesy of Subject

After a ton of research, I began to realize that psychedelics arent the hippie drug they used to be considered. In fact, research centers at Johns Hopkins University, New York University and the University of California, Berkeley, have begun to study the potential of psilocybin and other psychedelics to help a range of ills, including depression, anxiety, addition and eating disorders. The treatments are administered in research settings, with therapists in the room to keep watch over a person who has taken a precise dose of psychedelics. The treatment is also often combined with psychotherapy.

I couldn't get psychedelic therapy at Johns Hopkins, the closest hospital to me that offered it. They required treatment resistant depression, and since I didn't try antidepressants, I didn't qualify.

Instead, in January 2018, my husband began the process of growing psilocybin mushrooms himself. After a lot of research into legitimate sellers, we ordered mushrooms spores online its legal because the spores themselves dont contain psylocibin and started growing them in our bedroom. I don't recommend anyone do this and we didnt say a word to anyone about it. Daniel and I were local government employees, and I was taking the biggest risk of my life. Once the spores grew into mushrooms, which do contain psilocybin, we were breaking the law. I was terrified of getting caught and losing everything. But by that point, my mental health was hanging by a thread.

My lowest point was on Valentines Day, when I told my husband I was hearing voices.

My lowest point was on Valentines Day 2018 when Daniel and I went to lunch and I told him I was hearing voices. The look on his face said it all. His way of getting me in front of a professional was to suggest we go to couples therapy. And it was true that our marriage was struggling. We were not communicating with each other. We were sleeping on the very edges of the bed. We were constantly fighting. And truthfully it was easier to focus on our marriage than on myself.

Couples therapy provided some relief in our marriage, but it was not addressing the core of my deep depression. Our therapist recommended that I find a one-on-one therapist (I'd stopped going to one I had previously seen), but the time and financial commitment were too much and the depression had stripped me of nearly all my motivation to try to help myself. Finally, by March, I got to the point where I no longer wanted to live. I would fantasize about going to the roof of my building at work and what it would be like to jump. Every time I walked across the street, I envisioned a car turning the corner quickly and hitting me. I had panic attacks about once a week where I would punch my body.

I convinced myself that my kids would be better off with a different woman as their mother. My parents, who are immigrants from Iran, knew what was going on, but depression isn't really discussed in Iranian culture. My husband told me later that he called my mom several times to try to figure out how to help me, but neither of them really knew what to do. But he picked up all the household duties and childcare and encouraged me to get out of the house. He helped me work through panic attacks and allowed me as much alone time as I needed.

The first batch of mushrooms matured by April. I wasnt interested in tripping, so after reading deeply about other people's experiences and dosing approaches, I decided that whats called microdosing was right for me. I bought a small digital scale and measured out the tiniest amount, less than half a gram of a mushroom. I'd eat it with my breakfast and go to work. Again, I don't recommend this it's illegal and I didn't have a doctor monitoring me. But desperation is a powerful motivator.

I took my first microdose in April, and I started to notice a big difference three days later. Depression had made me feel very detached from my body and a bit disassociated from what was going on around me, like I was just going through the motions. Microdosing mushrooms made me feel very present in my body. There were no hallucinations or other symptoms you might associate with a psychedelic experience. I compare the feeling to getting eight hours of sleep, having a good workout and drinking the perfect amount of coffee. I just felt sharp and ready for my day.

Some of the numbness from depression started to lift. I could smell and taste things like normal again. My husband said I was walking taller, speaking differently and engaging with my children again. As the fog started to lift, I began to get even more invested in my own recovery, and I was motivated to return to one-on-one therapy.

After my first microdose, there were no hallucinations. It felt like getting eight hours of sleep and drinking the perfect amount of coffee.

I was microdosing mushrooms about three times a week and starting to feel a lot better, more like myself. But when my supply of mushrooms ran out and after a couple attempts of growing more mushrooms failed, my depression symptoms started to creep back. A friend suggested I try ayahuasca, a hallucinogenic tea made from the leaves of a South American shrub. The practice of drinking it for mental and spiritual healing originated thousands of years ago; the ceremonies are often lead by shamans.

I nervously participated in a few ceremonies. The experience can be difficult to describe, but ayahuasca opened my mind and allowed me to face and process my trauma. It didn't cure my depression, but after the ceremonies, I began to understand that the solution to my issues is not found in anything or anyone except myself. Knowing that I had all the tools within me already was a powerful feeling.

I hated that I had to sneak around and feel ashamed about ingesting two substances, mushrooms and ayahuasca, that literally grow out of the ground. I wanted more people to be aware of the potential benefits of psychedelics, so I started to explore what a campaign in D.C. to legalize entheogens, which are naturally occurring plants or fungi like psilocybin mushrooms, ayahuasca and others that can initiate altered states of consciousness that inspires mental or spiritual growth and healing, would look like. At that time, two U.S. cities, Denver and Oakland, had legalized them, and I reached out to the person who had led the campaign in Denver for advice.

Pretty early on, I realized that if I wanted the referendum, Initiative 81, to be successful, I needed to be the face of the campaign. It's very disarming when a message about psychedelics comes from a someone who might sit beside you at a PTA meeting. So, I became the Chairwoman of the Campaign to Decriminalize Nature DC and we launched the campaign and website with my story at the center and very credible research about the mental benefits of psychedelics from Johns Hopkins and NYU right alongside it.

Courtesy of Subject

I was fully prepared for blowback, to be called a bad mother and wife, but I didnt get much of that. When we held public meetings, a few people said, these substances could harm children and thats an unnecessary risk to take. But my response was that we have all sorts of things in our homes that can harm children scissors, knives, alcohol, medication. We protect our kids from these things, and we can protect our kids from entheogens, too.

We actually knew well before voting day that we were going to win. But when I heard the results 76% of voters approved the referendum I was shocked. Initiative 81 doesnt legalize entheogens or reduce penalties for having them. Rather, it decriminalizes them by making planting, buying or using them among the police departments lowest law enforcement priorities.

Mental health, especially for women and moms, isnt talked about nearly enough. Everyone feels like theyre the only ones having issues, but the truth is, one in nine new mothers experience postpartum depression. As my name and face came to be associated with the campaign, I found out that a lot of my friends were dealing with similar issues. Some of them hated to be medicated and were so happy to have another potential option. Not to mention that the pandemic has made nearly everyone so stressed and persistently anxious. Were all just trying to make it through. When this is over, were going to have a lot of mental health ramifications to deal with. And I think psychedelics can help play a role in the healing.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Here is the original post:

Magic Mushrooms Helped Me Cope With My Severe Postpartum Depression - GoodHousekeeping.com

PALM BEACH, Fla., June 8, 2021 /PRNewswire/ -- The illegal drugs of the 1960's are becoming highly valued drugs for various new therapeutic uses across a growing list of maladies. The door of previously prohibited drugs has been opening and it appears that there will be more treatments, more surprises and more revenues as the door continues to open. Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences. Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD. The rising prevalence of mental depression and anxiety and availability of off-label drugs are the major drivers which has propelled the demand of the psychedelic drugs market in the next several years. A reportfrom Data Bridge Market Research projected that the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 6,433.94 Million by 2028. Active companies in the markets this week include: COMPASS Pathways plc (NASDAQ: CMPS), Silo Pharma, Inc. (OTCQB: SILO),MindMed Inc.(NASDAQ: MNMD), Numinus Wellness Inc. (OTCPK: LKYSF)(TSXV: NUMI), Cybin Inc.(OTCQB:CLXPF) (NEO:CYBN).

But another reportfrom ResearchAndMarkets shows even more optimism in the market prediction that The Psychedelic Drugs Market size is projected to reach USD 10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. The awareness campaigns have encouraged people to select appropriate treatment for mental disorders procedures and professionals which is increasing the demand of psychedelic drugs and the rising awareness towards mental health is acting as a driver for the psychedelic drugs market Increasing research and development expenditure in the psychedelic drugs is creating new opportunities in the psychedelic drugs market, thus increasing R&D activities in psychedelic drugs is acting as an opportunity for the growth of the psychedelic drugs market."

Silo Pharma, Inc. (OTCQB: SILO) BREAKING NEWS: Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson's and Bipolar Patients - Silo Pharma, Inc., a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it hasentered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson's, Bipolar disorder, and chronic back pain.

Eric Weisblum, CEO of Silo Pharma commented "Inflammation is a common mechanism across numerous physical diseases. Inflammation has specifically been implicated in the pathophysiology of Parkinson's Disease,chronic pain, and bipolar disorder. Psilocybin and related compounds have shown strong anti-inflammatory effects in non-human animals, raising the possibility that reducing inflammation is a possible mechanism underlying psilocybin's positive treatment effects in multiple disorders. A better understanding of the anti-inflammatory effects of psilocybin has potential to allow for optimization and personalization of psilocybin treatment."

The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF. The TrPR brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA, and related compounds impact the brain and other organ systems. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments. Formoreinformation,visit http://www.silopharma.com

For more information about SILO please click herehttp://bit.ly/silo-news-6-8

Other recent developments in the markets include:

COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has recently reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists.

The data from the randomized, double-blind, placebo-controlled, phase I trial conducted at King's College London, will be presented today at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, by Dr James Rucker, Consultant Psychiatrist and Senior Clinical Lecturer in Psychopharmacology at King's College London's Institute of Psychiatry, Psychology and Neuroscience (IoPPN). Initial results from the study were published in December 2019. The results published today present a more in-depth analysis of cognitive data and showed some trends of positive effects, but these were minor and call for further exploration in clinical populations.

MindMed(NASDAQ: MNMD), a leading psychedelic medicine biotech company, recently announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the University Hospital Basel Liechti Lab, inBasel, Switzerland.

The results of this study indicate that pharmacogenetic testing prior to LSD-assisted treatment may inform LSD dose selection at the individual patient level. Dr.Matthias Liechtisaid, "This is the first data on the pharmacogenetics of LSD. The results indicate that a test of the metabolic function of a patient by CYP2D6 phenotyping and genotyping can be used to adjust the dose of LSD. Such information is important for the further development of LSD into a medication and could ultimately help to personalize patient treatment."

Cybin Inc.(OTCQB:CLXPF) (NEO:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, recently announced the sponsorship of Kernel's feasibility study of its Kernel Flow technology to measure Ketamine's psychedelic effect on cerebral cortex hemodynamics.

On January 11, 2021 Cybin announced that it would be partnering with Kernel to leverage Kernel's proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The Kernel Flow device is the first-of-its-kind that uses quantitative neuroimaging technology that can measure brain activity in real time using a wearable helmet during psychedelic treatments.

Numinus Wellness Inc. (OTCPK: LKYSF)(TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, andOptimi Health Corp.(CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, have met another early milestone in the development of an initial all natural psilocybin extract.

Optimi and Numinus, through Impact Clinical Trials Accelerator at theUniversity of Calgary("Impact"), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab inBritish Columbia, Canada.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Silo Pharma, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email:[emailprotected] +1(561)325-8757

SOURCE FinancialNewsMedia.com

See the original post here:

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years - PRNewswire

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor LiveChats on social media streams. Over 170,000 investors have participated in Wall Street Reporters livestream events in the past 30 days.

Red Light Holland (OTC: TRUFF) (CSE: TRIP) CEO Todd Shapiro: Psychedelics is Next Billion Dollar Market Opportunity

In a recent presentation on Wall Street Reporters NEXT SUPER STOCK livestream, Red Light Holland (OTC: TRUFF) (CSE: TRIP), CEO Todd Shapiro updated investors on the TRUFFs latest market expansion and success in the psychedelics sector, and major new growth opportunities in coming months. TRUFF produces and sells recreational grade psychedelic Magic Truffles to the current legal adult use market in the Netherlands, and is planning global expansion as legislation is rapidly changing globally.

TRUFF: The Tesla of Psychedelics

Todd was joined by cannabis industry pioneer and TRUFF advisory board chairman, Bruce Linton who shared his perspective on TRUFFs growth opportunities. Also joining the livestream was TRUFF CTO Sarah Hashkes who shared the companys unique technology-driven marketing and branding strategy for psychedelics, which has been likened by some investors as the Tesla of Psychedelics

Watch (OTC: TRUFF) Next Super Stock livestream Video: https://bit.ly/3u4aGR4

June 10 - TRUFF closes acquisition of 80% stake in Happy Caps Mushroom Farm based in in Nova Scotia, Canada. Happy Caps is a unique gourmet mushroom farm, cleverly positioned in the mushroom plug spawn business, selling fresh mushrooms for the wholesale market and specializing in 'grow your own mushroom kits' with sales in Canada and the United States. The transaction is immediately revenue accretive, and the Company will aggressively pursue additional revenue growth opportunities, including potentially introducing Happy Caps' products to Europe via SR Wholesale, RLH Netherlands B.V.'s wholly-owned wholesale company which has established a distribution network of over 400 companies that sell products across Europe.

June 8 - TRUFF closes acquisition of Radix Motion Inc., a technology and innovation company focused on empowering the psychedelic ecosystem with embodied technology, including augmented reality, virtual reality, and interactive holograms. "Psychedelics increase the plasticity in our brain and I believe the future of psychedelics will be using technology like ours to create support structures and customizable settings that will allow for tight feedback loops to help people achieve personal growth," said Sarah Hashkes, the CEO of Radix Motion and CTIO of Red Light Holland. "The broader vision we have for Radix Motion is utilizing my neuroscience research in movement data and psychedelics with Co-Founder Matthew Hoe's expertise in immersive technology and AR/VR to create healthy bridges between our body and technology. With Red Light Holland's support, we can further our vision and build technology that increases the bandwidth of human connection by linking us to our body and to each other in alignment with the magic of psychedelics."

Watch (OTC: TRUFF) Next Super Stock livestream Video: https://bit.ly/3u4aGR4

Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP) CEO, Dr. Guy Chamberland: Expecting to Launch 3 New Cannabinoid-Derived Drugs in 2022 - Addressing $200 Billion Market Opportunities

In a recent presentation at Wall Street Reporters NEXT SUPER STOCK livestream, Tetra Bio-Pharma (OTC: TBPMF) CEO, Dr. Guy Chamberland shared TBPMFs advanced pipeline of cannabinoid derived drugs targeting $200 billion addressable market opportunities including pain, inflammation, oncology, and sepsis.

TBPMF boasts one of the most advanced pipelines of Cannabinoid-derived medicines, supported by the urgent need for non-opioid alternatives to treat pain and inflammation. Significantly, TBPMFs portfolio of IP and patents is spearheaded by a team experienced at bringing new drugs to market.

TBPMF now has 3 drugs in the advanced clinical stages, which it expects to bring to market in 2022: Quixleef targeting pain management, a $58 billion market opportunity, ARDS-003 immunomodulator which is a $132 billion market opportunity, and PPP-003 for ophthalmic inflammation indication - a $31 billion market.

Compelling for investors, TBMPF has multiple near-term catalysts in place, and with a current valuation of about $50 million, TBPMF is trading at a just a small fraction of its peer group in the biotech space, with similar pipelines.

Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock video: https://bit.ly/2QzBElc

June 2 - TBPMF announces Health Canada has accepted its New Drug Submission (NDS) for REDUVO and has formally entered the final review phase in the drug review process. If successful, REDUVO will be issued a Notice of Compliance (NOC) as well as a Drug Identification Number (DIN) which permits Tetra to market the drug in Canada and indicates the drug's official approval in Canada. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection. The active pharmaceutical ingredient in REDUVO is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.

May 11 - TBPMF announces acceleration of a revolutionary Phase 2 clinical trial, PLENITUDE, to evaluate the safety and efficacy of the investigational cannabis medicine, QIXLEEF, for use in managing uncontrolled pain in patients with advanced cancer.

May 6 - TBPMF announces start of REBORN1 clinical trial. This trial is designed to evaluate the effect of the Company's inhaled proprietary drug formulation, QIXLEEF, against immediate release oral morphine sulfate on onset of pain relief in people living with cancer. QIXLEEF is a botanical drug product with a "fixed ratio" of THC and CBD and is inhaled through a Class 2 medical device vaporizer. REBORN1 is being conducted in the United States in collaboration with the Hassman Research Institute, a clinical research organization, who will enroll twenty adults living with breakthrough cancer pain (BTcP) and currently taking stable opioid treatment for breakthrough pain. This innovative Phase 2 pilot, proof-of-concept open-label crossover comparison study will assess whether inhaled QIXLEEF will control BTcP faster than immediate-release morphine sulfate tablets.

Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock video: https://bit.ly/2QzBElc

FansUnite (OTC: FUNFF) (CSE: FANS) Positioned for Exponential Revenue Growth in iGaming, E-Sports, Online Sports Betting

In their latest presentation at Wall Street Reporters NEXT SUPER STOCK livestream, FansUnite (OTC: FUNFF) (CSE: FANS) CEO Scott Burton, and President Darius Eghdami explained how FUNFFs latest distribution deal with an online casino games aggregator, sets the stage for exponential revenue growth opportunities. In the next 12 months, FUNFF plans to expand its current line from three games to twelve - while adding multiple aggregators for each game - reaching millions of new online casino customers worldwide. With each game generating as much as $500,000 in revenue per month for FUNFF - per online casino - and the potential to be in hundreds of online casinos - these numbers can quickly add up.

Watch FansUnite (OTC: FUNFF) NEXT SUPER STOCK Video: http://bit.ly/3sGSvAs

May 12 - FUNFF has entered a brand partnership with Cash Live Inc. to launch FansUnite branded live games on the Cash Live mobile app. FansUnite has a minority interest in Cash Live, a tech start-up that offers a new popular poker and social casino game show platform. Cash Live is a free-to-play gaming app that is designed for mobile devices and features daily live-streamed poker game shows paying out real cash to its winners.The first branded FansUnite game will be available on Wednesday, May 12th at 6:00 pm PT and will play down to a winner in under 20 minutes. The Cash Live mobile app can be downloaded in the App Store: https://cashlivepoker.page.link/FansUnite

April 14 - FUNNF reports record $28.3M in betting volume and a 136% increase in revenue for its McBookie subsidiary in Q1 2021, compared to same period last year.

Watch FansUnite (OTC: FUNFF) NEXT SUPER STOCK Video: http://bit.ly/3sGSvAs

Skylight Health Group (NASDAQ: SLHG) (TSX.V: SHG) CEO, Prad Sekar: Now At Inflection Point - Positioned for 10X Upside Revenue Growth Potential

Skylight Health Group (NASDAQ: SLHG) (TSX.V: SHG) was recently a featured presenter at Wall Street Reporters NEXT SUPER STOCK livestream investor conference. CEO Prad Sekar, outlined his vision for building Skylight into a multi-billion dollar business focused on the highly fragmented US healthcare market. Skylight already operates 30 clinics, in 14 states, with virtual telehealth overlay, serving over 120,000 patients - and is one of the fastest growing multi-disciplinary health systems in the United States.

Watch Skylight (NASDAQ: SLHG) Next Super Stock video: http://bit.ly/3qAZAAr

Skyllight is now at an inflection point. SLHG revenues are expected to be $56 million and $5.5 million EBITDA run rates, with a recently announced acquisition. SLHG boasts a profitable base of operations, no long-term debt and cash balance of $10 million. In his presentation, Skylight CEO Prad Sekar, explains how the company can increase revenues organically by about 10X, as it optimizes clinics for profitability by expansion of services to the existing patient base, with its proven business model, stating: "$200 Million Revenues Run Rate in 2021 Is Goal".

Watch Skylight (NASDAQ: SLHG) Next Super Stock video: http://bit.ly/3qAZAAr

June 7 - SLHG up-lists to NASDAQ from OTC BB to improve market access and liquidity access for retail and institutional investors globally.

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. http://www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context.Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K

About Wall Street Reporters Next Super Stock conference:

Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7

http://www.WallStreetReporter.com

More:

Next Super Stocks on the Move: Tetra Bio-Pharma, Red Light - GlobeNewswire